Vivimed Labs Limited (VIVIMEDLAB) AI Stock Analysis

• Market Cap: $406.28M
• Dividend Yield: N/A
• Average Volume (3M): N/A
• Price to Earnings (P/E): ―
• Beta (1Y): N/A
• Revenue Growth: -24.33%
• EPS Growth: 52.06%
• Country: IN
• Employees: 607
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -0.66
• Shares Outstanding: N/A
• 10 Day Avg. Volume: N/A
• 30 Day Avg. Volume: N/A
• PEG Ratio: 0.04
• Price to Book (P/B): -1.17
• Price to Sales (P/S): 0.35
• P/FCF Ratio: -4.76
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: Moderate Sell
• Number of Analyst Covering: 0

• Rating: 37 Underperform
• Price Target: ―

The most significant factor in the low overall stock score is the company's severe financial distress, characterized by declining revenues, persistent losses, and high leverage with negative equity. The lack of technical analysis data further compounds the uncertainty surrounding the stock. Without valuation metrics and earnings call insights, the investment outlook remains highly unfavorable.

Vivimed Labs Limited Business Overview & Revenue Model

Company Description

Vivimed Labs Limited, together with its subsidiaries, manufactures and sells active pharmaceutical ingredients (APIs), finished dosage formulations, specialty chemicals, and retail branded formulations in India, Mexico, Spain, Hungary, and internationally. It operates in two segments, Specialty Chemicals Business and Pharma Business. The company provides APIs and intermediates to generic and ethical companies; and branded formulations in therapeutic segments, such as ophthalmic, nutraceuticals, dermatology, and pain, as well as contract manufacturing of capsules and tablets, syrups and liquids, and nasal sprays and ointments. It also offers a range of hair dye intermediates for use in permanent, semi-permanent, and temporary hair colorant systems; oxidation dye couplers and bases to formulate various permanent and demi-permanent shades; direct dyes for semi-permanent formulations; and basic dyes for temporary, semi-permanent, and color-refresher shampoos and conditioners under the Jarocol name. In addition, the company manufactures and markets photochromic dyes under the Reversacol name; and anti-microbial actives for use in a range of applications, including plastics additives and anti-bacterial handwashes. Further, it offers photographic chemicals, such as black and white developers, and antifog additives for use in medical and industrial X-ray imaging, consumer photography, and litho-plate production for the graphic arts industry. Additionally, the company manufactures Favulous for the treatment of mild to moderate cases of Covid-19. Its products are used in home, personal, and industrial care segments. The company was incorporated in 1988 and is based in Hyderabad, India.

How the Company Makes Money

Vivimed Labs Limited generates its revenue primarily through the sale of its active pharmaceutical ingredients (APIs) and finished formulations to various markets worldwide. The company also earns income from its specialty chemicals division, which supplies ingredients for personal care products. Key revenue streams include partnerships and collaborations with global pharmaceutical companies, contract manufacturing services, and the distribution of its own branded generic and specialty products. Strategic alliances and licensing agreements further contribute to Vivimed Labs' earnings, allowing it to expand its market reach and leverage expertise in research and development.

Vivimed Labs Limited Financial Statement Overview

Summary

Vivimed Labs Limited faces severe financial distress across all verticals. The income statement reflects declining revenues and persistent losses, while the balance sheet shows high leverage with negative equity, raising questions about the company's solvency. Cash flow challenges further exacerbate the situation, with negative free cash flow and inconsistent operating cash flow. The company needs substantial restructuring and strategic changes to stabilize its financial position and return to growth.

Income Statement

The income statement reveals significant challenges, with consistent revenue decline and negative profit margins. Gross profit margin dropped sharply over the years, and the company has reported negative EBIT and net income for consecutive years. This indicates a struggling operational efficiency and severe profitability issues, with no signs of immediate improvement.

Balance Sheet

The balance sheet demonstrates a concerning financial position. The debt-to-equity ratio is not calculable due to negative equity, indicating insolvency risk. Additionally, the company's total liabilities exceed its total assets, presenting a critical leverage issue. The return on equity (ROE) is also not calculable due to negative equity, further highlighting financial instability.

Cash Flow

The cash flow statement highlights substantial negative free cash flow, though there was a brief period of positive operating cash flow in 2023. The company's operating cash flow and free cash flow remain volatile and insufficient to cover operating expenses, indicating cash management concerns and sustainability issues.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	1.43B	1.16B	1.49B	1.87B	2.37B	8.61B
Gross Profit	508.66M	77.98M	705.71M	-928.65M	838.04M	5.07B
EBITDA	-353.93M	-86.77M	-246.69M	-1.86B	-67.91M	336.05M
Net Income	-463.30M	-319.61M	-454.46M	-3.29B	-676.50M	-777.95M
Balance Sheet
Total Assets	0.00	9.21B	9.51B	9.88B	12.66B	12.89B
Cash, Cash Equivalents and Short-Term Investments	16.26M	7.08M	717.79M	37.62M	71.84M	64.31M
Total Debt	0.00	3.76B	3.79B	3.81B	2.78B	2.53B
Total Liabilities	54.61M	9.56B	9.56B	9.49B	9.02B	8.58B
Stockholders Equity	-54.61M	-351.69M	-54.61M	394.23M	3.64B	4.32B
Cash Flow
Free Cash Flow	188.16M	-86.28M	-260.30M	303.54M	-6.75B	5.67B
Operating Cash Flow	188.16M	-40.97M	-239.91M	138.12M	-6.58B	5.67B
Investing Cash Flow	0.00	-45.31M	282.88M	-49.68M	5.23B	4.04B
Financing Cash Flow	0.00	73.10M	-60.32M	-162.44M	-103.80M	-10.15B

Vivimed Labs Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BALAXI	64 Neutral	₹476.44M	11.90	10.82%	―	―	―
INDSWFTLTD	53 Neutral	₹850.39M	0.30	-70.45%	―	2.59%	1891.61%
BIOFILCHEM	52 Neutral	₹679.76M	24.28	2.97%	―	-31.82%	341.44%
LASA	50 Neutral	₹589.69M	-1.78	-17.63%	―	25.82%	-69.86%
VIVIMEDLAB	37 Underperform	$406.28M	―	―	―	-24.33%	52.06%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%